Voyager Therapeutics, Inc. (NASDAQ:VYGR) Short Interest Update

by · The Cerbat Gem

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 2,990,000 shares, a drop of 29.6% from the September 15th total of 4,250,000 shares. Based on an average daily trading volume, of 454,700 shares, the days-to-cover ratio is currently 6.6 days.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. increased its position in shares of Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after acquiring an additional 1,300 shares in the last quarter. Plato Investment Management Ltd purchased a new position in Voyager Therapeutics during the 1st quarter worth approximately $38,000. SG Americas Securities LLC acquired a new stake in shares of Voyager Therapeutics in the second quarter worth $85,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Voyager Therapeutics by 104.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock worth $97,000 after buying an additional 5,311 shares during the period. Finally, ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics during the first quarter valued at $101,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on VYGR shares. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Wedbush dropped their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $17.83.

Read Our Latest Analysis on Voyager Therapeutics

Voyager Therapeutics Stock Up 4.5 %

NASDAQ:VYGR traded up $0.31 during trading hours on Friday, reaching $7.18. 403,650 shares of the company’s stock were exchanged, compared to its average volume of 597,713. The company has a market capitalization of $390.55 million, a P/E ratio of -143.60 and a beta of 0.91. Voyager Therapeutics has a 12 month low of $5.71 and a 12 month high of $11.72. The business’s 50-day simple moving average is $6.52 and its two-hundred day simple moving average is $7.77.

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. During the same period last year, the company posted ($0.51) EPS. As a group, sell-side analysts anticipate that Voyager Therapeutics will post -1.44 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Further Reading